ZTA Biotech, a Budapest-based biotech start-up, announced 6 January the breakthrough development of a COVID-19 antibody (IgG) test using the ELISA protocol – and is offering the intellectual property rights to licensees or a sole-rights purchaser.
This new detection method represents a significant step forward in COVID-19 IgG antibody testing to determine if patients have had COVID-19 and if they might still have immunity to the disease . Early results have proven 100% in specificity after testing 280 samples, and 100% sensitivity by testing 260 samples of recovered and symptomatic patients.
The COVID-19 IgG test using the ELISA (Enzyme Linked Immunosorbent Assay) protocol is designed for use in the post-vaccination period. With a potential market of 5.8 billion people, the formula has massive sales potential across the globe. ZTA Biotech is offering the intellectual property rights to licensees or to a sole-rights purchaser, in order to help bring this ELISA formula to market. The company is calling on brokering services of specialized companies to facilitate an open and transparent dialogue between ZTA Biotech and potential clients.
The test is based on selective detection of human IgG antibodies that bind to SARS- CoV-2 antigens coated on the wells of the microplate and can be used for qualitative and semi-quantitative determination of human IgG. After the completion of the first critical reaction step, all unbound serum components are fully washed away and a series of reactions occur that will lead to a photometrically measurable step where the intensity of the obtained colour is proportional to the quantity of SARS-CoV-2 IgG antibodies in the original sample. The whole process takes less than 2 hours to complete and can be fully automated. Also, it can be easily converted to a quantitative test, if needed.
The test was independently validated. Technical data is available upon request, the company says. ZTA Biotech points out that the kit is extremely stable, has a long shelf life and opened kits are usable up to 3 months at storage temperatures of 5°C.
In addition, ZTA Biotech notes that the test can be adapted to potential virus mutations, based on sequencing data.
For more information, visit: http://ztabiotech.com